Mesothelin promotes the migration of endometrioid carcinoma and is associated with the MELF pattern.

MELF cadherin-6 endometrioid carcinoma mesothelin migration

Journal

Pathology, research and practice
ISSN: 1618-0631
Titre abrégé: Pathol Res Pract
Pays: Germany
ID NLM: 7806109

Informations de publication

Date de publication:
24 Aug 2024
Historique:
received: 04 08 2024
revised: 23 08 2024
accepted: 23 08 2024
medline: 26 8 2024
pubmed: 26 8 2024
entrez: 25 8 2024
Statut: aheadofprint

Résumé

Mesothelin (MSLN) is expressed in the mesothelium in normal tissues but is overexpressed in various malignant tumors. In this study, we searched for genes that were more frequently expressed in cases of endometrioid carcinoma (EC) with the MELF (microcystic, elongated, and fragmented) pattern using laser microdissection and RNA sequencing, and found that MSLN was predominantly expressed in cases with the MELF pattern. The role of MSLN in EC was analyzed by generating MSLN-knockout and -knockdown EC cell lines. MSLN promoted migration and epithelial-mesenchymal transition (EMT). Moreover, we found that cadherin-6 (CDH6) expression was regulated by MSLN. MSLN is known to bind to cancer antigen 125 (CA125), and we found that CA125 can regulate CDH6 expression via MSLN. Immunohistochemical investigations showed that MSLN, CA125, and CDH6 expression levels were considerably elevated in EC with the MELF pattern. The expression of CA125 was similar to that of MSLN not only in terms of immunohistochemical staining intensity but also the blood level of CA125. Our results showed that MSLN contributes to the migration and EMT of EC cells through upstream CA125 and downstream CDH6. Therefore, MSLN has potential as a therapeutic target for EC with the MELF pattern.

Identifiants

pubmed: 39182448
pii: S0344-0338(24)00473-4
doi: 10.1016/j.prp.2024.155562
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

155562

Informations de copyright

Copyright © 2024. Published by Elsevier GmbH.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Shinichiro Tahara (S)

Department of Pathology, Osaka University Graduate School of Medicine, Osaka, Japan.

Satoshi Nojima (S)

Department of Pathology, Osaka University Graduate School of Medicine, Osaka, Japan.

Tsuyoshi Takashima (T)

Department of Pathology, Osaka University Graduate School of Medicine, Osaka, Japan.

Daisuke Okuzaki (D)

Single Cell Genomics, Human Immunology, WPI Immunology Frontier Research Center, Osaka University, Osaka, Japan.

Eiichi Morii (E)

Department of Pathology, Osaka University Graduate School of Medicine, Osaka, Japan. Electronic address: morii@molpath.med.osaka-u.ac.jp.

Classifications MeSH